Dyadic announces successful toxicology data published in “toxicologic pathology”

Jupiter, fla., may 09, 2022 (globe newswire) -- dyadic international, inc. ("dyadic", "we", "us", "our", or the "company") (nasdaq: dyai), a global biotechnology company focused on deploying its proprietary c1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics, announced today the successful results and data received from the toxicology study of its dyai-100 covid-19 vaccine candidate. “toxicity and local tolerance of a novel spike protein rbd vaccine against sars-cov-2, produced using the c1 thermothelomyces heterothallica protein expression platform" has been published in “toxicologic pathology” 2022, vol. 50(3) 1–14”, an international peer-reviewed scientific journal. the toxicology study was performed under glp tox conditions by covance's envigo crs israel ltd (“envigo”).
DYAI Ratings Summary
DYAI Quant Ranking